Collectively, enforced RTK activation in GBM critically contributes to its malignant traits, including increased invasiveness [10], and many receptor tyrosine kinase inhibitors have been tested in the clinical setting either as monotherapy or in combination with other agents, including EGFR, PDGFR and VEGFR inhibitors (reviewed in [10]). The gene discussed is EGFR; the disease is glioblastoma.